These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19203501)

  • 21. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice.
    Takahashi T; Harris RC
    J Diabetes Res; 2014; 2014():590541. PubMed ID: 25371905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.
    Oltean S; Qiu Y; Ferguson JK; Stevens M; Neal C; Russell A; Kaura A; Arkill KP; Harris K; Symonds C; Lacey K; Wijeyaratne L; Gammons M; Wylie E; Hulse RP; Alsop C; Cope G; Damodaran G; Betteridge KB; Ramnath R; Satchell SC; Foster RR; Ballmer-Hofer K; Donaldson LF; Barratt J; Baelde HJ; Harper SJ; Bates DO; Salmon AH
    J Am Soc Nephrol; 2015 Aug; 26(8):1889-904. PubMed ID: 25542969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
    Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R
    Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatty acid binding protein 3 as a potential mediator for diabetic nephropathy in eNOS deficient mouse.
    Ozawa S; Ueda S; Li Y; Mori K; Asanuma K; Yanagita M; Nakagawa T
    Biochem Biophys Res Commun; 2014 Nov; 454(4):531-6. PubMed ID: 25450688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link?
    Quaggin SE; Coffman TM
    J Am Soc Nephrol; 2007 Feb; 18(2):364-6. PubMed ID: 17259594
    [No Abstract]   [Full Text] [Related]  

  • 26. The effects of adenosine A2B receptor inhibition on VEGF and nitric oxide axis-mediated renal function in diabetic nephropathy.
    Patel L; Thaker A
    Ren Fail; 2014 Jul; 36(6):916-24. PubMed ID: 24678970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
    Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
    Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
    Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
    Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nodular lesions and mesangiolysis in diabetic nephropathy.
    Wada T; Shimizu M; Yokoyama H; Iwata Y; Sakai Y; Kaneko S; Furuichi K
    Clin Exp Nephrol; 2013 Feb; 17(1):3-9. PubMed ID: 23100177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
    Masuda K; Tanabe K; Ujike H; Hinamoto N; Miyake H; Tanimura S; Sugiyama H; Sato Y; Maeshima Y; Wada J
    PLoS One; 2018; 13(4):e0195779. PubMed ID: 29641565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.
    Kosugi T; Heinig M; Nakayama T; Connor T; Yuzawa Y; Li Q; Hauswirth WW; Grant MB; Croker BP; Campbell-Thompson M; Zhang L; Atkinson MA; Segal MS; Nakagawa T
    Am J Pathol; 2009 Apr; 174(4):1221-9. PubMed ID: 19246639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice.
    Cheng H; Wang H; Fan X; Paueksakon P; Harris RC
    Kidney Int; 2012 Dec; 82(11):1176-83. PubMed ID: 22785174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.
    Nakagawa T; Sato W; Kosugi T; Johnson RJ
    J Diabetes Res; 2013; 2013():184539. PubMed ID: 24386643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial dysfunction as a potential contributor in diabetic nephropathy.
    Nakagawa T; Tanabe K; Croker BP; Johnson RJ; Grant MB; Kosugi T; Li Q
    Nat Rev Nephrol; 2011 Jan; 7(1):36-44. PubMed ID: 21045790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
    Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
    Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy.
    Hohenstein B; Hugo CP; Hausknecht B; Boehmer KP; Riess RH; Schmieder RE
    Nephrol Dial Transplant; 2008 Apr; 23(4):1346-54. PubMed ID: 18065828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low molecular-weight fucoidan protects against hindlimb ischemic injury in type 2 diabetic mice through enhancing endothelial nitric oxide synthase phosphorylation.
    Liu T; Wang Z; Chen X; You H; Xue J; Cai D; Zheng Y; Xu Y; Luo D
    J Diabetes; 2018 Nov; 10(11):820-834. PubMed ID: 29633569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.
    Carranza K; Veron D; Cercado A; Bautista N; Pozo W; Tufro A; Veron D
    Nefrologia; 2015; 35(2):131-8. PubMed ID: 26300505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production.
    Prabhakar S; Starnes J; Shi S; Lonis B; Tran R
    J Am Soc Nephrol; 2007 Nov; 18(11):2945-52. PubMed ID: 17928507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.